Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Geriatrics | Internal Medicine | Nursing | Pharmacy | Anesthesiology & Pain | Journal

Back to Journal Articles

Different Opioids Linked to Different Risks of Events

Last Updated: December 15, 2010.

 

Subjects were Medicare beneficiaries prescribed five common opioids for nonmalignant pain

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The risks of adverse events among older adults using opioid analgesics for nonmalignant pain varies by agent, according to research published in the Dec. 13/27 issue of the Archives of Internal Medicine.

WEDNESDAY, Dec. 15 (HealthDay News) -- The risks of adverse events among older adults using opioid analgesics for nonmalignant pain varies by agent, according to research published in the Dec. 13/27 issue of the Archives of Internal Medicine.

Daniel H. Solomon, M.D., M.P.H., of Brigham and Women's Hospital in Boston, and colleagues analyzed data from 6,275 matched Medicare beneficiaries in each of five opioid groups who began opioid therapy for nonmalignant pain. Subjects were prescribed hydrocodone bitartrate, codeine phosphate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride.

The researchers found that the groups had similar risk of cardiovascular events 30 days after starting opioid treatment, but the risk was higher with codeine after 180 days (rate ratio [RR], 1.62). After 30 days of exposure, the risk of fractures was lower with tramadol and propoxyphene compared to hydrocodone (RRs, 0.21 and 0.54, respectively). The risk of gastrointestinal safety events was similar across groups. Oxycodone and codeine users had more all-cause mortality after 30 days compared to hydrocodone users (RRs, 2.43 and 2.05, respectively).

"In summary, we explored possible differences in risk between opioids commonly used for nonmalignant pain and found that the risk varied by agent across many of the adverse events examined," the authors conclude. "The risks were substantial and translated into numbers needed to treat that would be considered clinically significant. Our findings regarding cardiovascular risk were surprising and require validation in other data sets."

A co-author disclosed unpaid relationships with Pfizer.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: Nutrition Intervention Linked to Benefits in Older Adults Next: CMSTO: Ipilimumab Beneficial in Late-Stage Lung Cancer

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.